[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dementia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dementia":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,265,0,25,[9,48,81,112,133,176,202,228,260,291,318,339,369,388,408,431,455,473,503,534,562,600,616,638,664],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100210276","genetic-characterization-of-movement-disorders-and-dementias-100210276",false,"NCT02014246","Genetic Characterization of Movement Disorders and Dementias","The Genetic Characterization of Movement Disorders and Dementias","* INCLUSION CRITERIA\n\nFor Patients:\n\n* Diagnosis of a movement disorder or dementia by a neurologist or other qualified professional and accompanied by sufficient clinical and\u002For laboratory evidence to support the diagnosis\n* Confirmation of a movement disorder or dementia by study investigators or a qualified clinician by physical examination and\u002For review of medical records\n* Ages 18 and above\n* Able to provide consent or, in the case of minors, or cognitive impairment, have a legally-authorized representative to provide consent\n* Able to understand and participate in study procedures or for those without consent capacity, able to participate in study procedures AND has a legally authorized representative that understands the study procedures and can consent on their behalf.\n\nFor unaffected family members of patients:\n\n* Unaffected relative of a patient diagnosed with a movement disorder or dementia enrolled in this protocol. For these purposes, we define a family member as an individual for which there is a demonstrable relationship with the proband in the pedigree. This is a standard approach used in family-based studies. Furthermore, the related patient (defined as a family member diagnosed with the disease of interest) must be enrolled in the study.\n* Ages 18 and above\n* Able to provide consent\n* Able to understand and participate in study procedures\n\nFor unrelated healthy control individuals:\n\n* Be in good general health\n* Have no known movement disorder or dementia, or family member with a movement disorder or dementia\n* Age 18 and above\n* Able to provide consent\n* Able to understand and participate in study procedures\n\nEXCLUSION CRITERIA\n\nFor patients:\n\n-An identifiable, non-genetic etiology for the movement disorder or dementia, such as a specific environmental exposure, birth injury, metabolic disorder, or brain infection such as encephalitis\n\nFor all participants:\n\n* Clinically significant anemia that would make phlebotomy unsafe, and participant unwilling to provide saliva sample.\n* Clinically significant bleeding that would make phlebotomy unsafe, and participant unwilling to provide saliva sample.\n* Any medical condition that would make phlebotomy unsafe or undesirable, such as a serious medical illness like unstable heart disease, or unstable chronic obstructive pulmonary disease, and participant unwilling to provide saliva sample.",true,"ALL","18 Years","120 Years",{"count":22,"type":23},12000,"ESTIMATED","OBSERVATIONAL","Background:\n\nThere are two basic types of movement disorders. Some cause excessive movement, some cause slowness or lack of movement. Some of these are caused by mutations in genes. On the other hand, dementia is a condition of declining mental abilities, especially memory. Dementia can occur at any age but becomes more frequent with age. Researchers want to study the genes of families with a history of movement disorders or dementia. They hope to find a genetic cause of these disorders. This can help them better understand and treat the diseases. This study will not be limited to a particular disorder, but will study all movement disorders or dementias in general. This study will perform genetic testing to identify the genetic causes of movement disorders and dementia. Today, genetic testing can be done to analyze multiple genes at the same time. This increases the chances of finding the genetic cause of movement disorders and dementias.\n\nObjectives:\n\nTo learn more about movement disorders and dementia, their causes, and treatments.\n\nEligibility:\n\nAdults and children with a movement disorder or dementia, and their family members.\n\nHealthy volunteers.\n\nDesign:\n\nParticipants will be screened with medical history and blood tests. Some will have physical exam.\n\nParticipants will give a blood sample by a needle in the arm. This can be done at the clinic, by their own doctor, or at home. Alternatively, a saliva sample may be provided if a blood sample cannot be obtained.\n\nParticipants can opt to send an extra blood sample to a repository for future study. Genetic test will be done on these samples. The samples will be coded. The key to the code will remain at NIA. Only NIA investigators will have access to the code key. Participants can request to receive results of the tests.\n\nParticipation is generally a single visit. Participants may be called back for extra",[27,28],"Dementia","Movement Disorder",[30,31,32,33,34],"Movement Disorders","Polymorphisms","DNA","Lymphoblastoid Cell Lines","Natural History","RECRUITING","2026-08-20",{"date":38,"type":39},"2026-08-21","ACTUAL",{"date":41,"type":39},"2003-07-14",{"date":43,"type":4},"2059-12-31",{"name":45,"class":46},"National Institute on Aging (NIA)","NIH",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100488671","enhancing-shared-decision-making-to-guide-care-for-people-with-dementia-and-diabetes-100488671","NCT05643144","Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes","Enhancing Shared Decision-making to Prompt and Guide Individualized Care for People With Alzheimer's Disease and Diabetes","CGM ASSIST","Patient-Caregiver Dyad Inclusion Criteria:\n\n* patient must have dual diagnosis of MCI or ADRD and diabetes (DM)\n* patient must have active prescriptions for DM\n* patient must have had at least one visit to an Eskenazi or IU Health primary care clinic within 12 months\n* patient must be able to provide assent and have a legally authorized representative (LAR) consent on their behalf if patient lacks capacity to consent\n* patient must have a caregiver aged 18 years or older who interacts daily, or almost daily, with the patient\n* patient and caregiver must both speak English\n* patient and caregiver must both reside in the community\n* dyad must have internet access\n\nPatient-Caregiver Dyad Exclusion Criteria:\n\n* patient has terminal illness\n* use of an automated insulin delivery system\n* patient is receiving dialysis\n* patient is taking ascorbic acid during monitoring period\n* patient has existing implanted medical devices\n* patient has a bleeding disorder\n* patient has a pre-existing arm skin lesions\n* patient has an allergy to medical adhesive or isopropyl alcohol\n* patient has plans for imaging or diathermy treatment during the study period","65 Years",{"count":58,"type":23},62,"INTERVENTIONAL",[61],"NA","The goal of this study is to test CGM ASSIST. This is a digital tool that uses an interactive information display-an easy-to-read screen designed to help people with dementia (or memory loss) and diabetes, as well as their caregivers and doctors.\n\nManaging diabetes is often difficult for people with memory issues. This study uses a Continuous Glucose Monitor (CGM), which is a device that tracks blood sugar levels in real-time. CGM ASSIST adds a new way to see this data through interactive displays. These displays show clear information and medical guidelines to help patients and caregivers make sense of the glucose readings.\n\nThe study aims to:\n\n* Increase Awareness: Help patients and caregivers recognize the dangers of low blood sugar (hypoglycemia) and how to treat it.\n* Improve Teamwork: Encourage \"shared decision-making,\" where patients, caregivers, and doctors work together to make health choices.\n* Test Feasibility: See if it is easy and helpful for people with memory loss to use these interactive displays in their daily lives.\n* Understand Experiences: Learn how the thoughts and feelings of patients and families affect how they manage diabetes.\n\nBy using these interactive displays, the researchers hope to make it easier for families to understand their health needs and communicate better with their medical team.\n\nParticipants will:\n\n* Answer a survey about how they manage their diabetes\n* Learn how to use a Continuous Glucose Monitor and wear it for 14 days\n* Answer 3 brief telephone surveys during these 14 days\n* Complete a clinic visit with their doctor and answer a final survey on how this visit went using the CGM ASSIST report",[64,65,27,66],"Diabetes","Alzheimer's Disease (Incl Subtypes)","Hypoglycemia",[68,69,70,71],"Continuous glucose monitoring","Shared decision-making","Human factors","Primary care","2026-08-19",{"date":36,"type":39},{"date":75,"type":23},"2026-09-07",{"date":77,"type":23},"2027-06-30",{"name":79,"class":80},"Indiana University","OTHER",{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":59,"phases":91,"briefSummary":92,"conditions":93,"keywords":98,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":47},"100652907","personalized-sensory-stimulation-urban-and-rural-dementia-care-100652907","NCT07778277","Personalized Sensory Stimulation: Urban and Rural Dementia Care","Smart Brain Health Promotion Service Integrating Personalized Sensory Stimulation: Practical Validation and Application in Urban and Rural Dementia Care Centers","Inclusion Criteria:\n\n* Aged ≥ 60 years\n* The score of MoCA between 10 to 25\n\nExclusion Criteria:\n\n* Diagnosis of other psychiatric or neurological disorders, and those with a history of neurological or psychiatric disorders that may affect cognitive assessment or performance. For example (but not limited to): Parkinson's disease, schizophrenia, major depressive disorder, epilepsy, severe traumatic brain injury with loss of consciousness, and stroke.\n* Drug, Nicotine or alcohol addictions\n* Serious heart, liver or kidney disorders, and visual, auditory or motor impairments interfering with neuropsychological tests.","60 Years",{"count":90,"type":23},90,[61],"As Taiwan transitions into a super-aged society, rising dementia rates have severely strained long-term care systems. Although current daycare centers provide multi-modal programs, they remain limited to behavioral training, lacking precise interventions targeting brain function and neuroplasticity or integrated non-invasive neuromodulation technologies. Furthermore, urban-rural disparities in resources, staffing allocation, and tech experience hinder practical deployment, with empirical research remaining scarce. Addressing this gap, this study investigates a smart brain health promotion model combining personalized gamma music stimulation and cognitive training for mild cognitive impairment and dementia, while evaluating its feasibility across diverse care settings.",[27,94,95,96,97],"Acoustic Stimulation","Healthcare Disparities","Precision Medicine","Cognitive Training",[27,99,100,101,102],"Gamma frequency auditory tone","Personalize intervention","Urban-rural disparities","Cognitive training","NOT_YET_RECRUITING","2026-08-18",{"date":38,"type":39},{"date":107,"type":23},"2026-09-20",{"date":109,"type":23},"2028-09-20",{"name":111,"class":80},"Chang Gung Memorial Hospital",{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":17,"sex":18,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":59,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":47},"100652551","study-protocol-the-efficacy-of-mushroom-to-reduce-cognitive-decline-in-at-risk-middle-aged-adults-and-young-olds-living-in-the-community-100652551","NCT07775833","Study Protocol: The Efficacy of Mushroom to Reduce Cognitive Decline in At-Risk Middle-aged Adults and Young-olds Living in the Community","Inclusion Criteria:\n\n* (1) Community-living adult aged 45 years to 80 years, AND\n* (2) Family history of Alzheimer's disease or having subjective cognitive (SCD) defined as \"self-reported memory problems that have been getting worse over the past year.\", AND\n* (3) Consume mushrooms no more than once a week, AND\n* (4) No dementia: CDR global score equal to zero.\n\nExclusion Criteria:\n\n* (1) Any diagnosis of neurological diseases (e.g., epilepsy, stroke) made by a clinician, OR\n* (2) Any diagnosis of psychiatric illnesses (e.g., depressive disorders) made by a clinician, OR\n* (3) Significant sensory or motor impairments, OR\n* (4) Known allergy to mushrooms or a history of serious food allergies, OR\n* (5) Participants with a history of gout, OR\n* (6) Diagnosed with hyperuricemia.","45 Years","80 Years",{"count":121,"type":23},600,[61],"The investigator's objective is to explore the definitive evidence of mushroom on cognitive functions among at-risk middle-aged and young-olds.\n\nThe investigator carefully designed a randomized controlled trial (RCT) to assess the role of mushrooms in promoting cognitive functioning among around 600 middle-aged adults and young-olds.\n\nParticipants were selected based on specific inclusion criteria, such as being community-living adults aged 45-80 years with a family history of dementia or subjective cognitive decline, while consuming mushrooms no more than once a week and having no dementia, along with the exclusion of individuals with neurological or psychiatric disorders and significant sensory or motor impairments. Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance",[27,125],"Cognitive Assessment",{"date":36,"type":39},{"date":128,"type":23},"2026-10",{"date":130,"type":23},"2030-12",{"name":132,"class":80},"National University of Singapore",{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":59,"phases":143,"briefSummary":144,"conditions":145,"keywords":151,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":47},"100651071","the-basic-s-feasibility-study-for-vascular-risk-reduction-100651071","NCT07755631","The BASIC-S Feasibility Study for Vascular Risk Reduction","Piloting an Integrated Lifestyle Intervention for Vascular Risk Reduction: The BASIC-S Feasibility Study","BASIC-S","Inclusion Criteria:\n\n* Adults aged 18 years and older currently employed at or recently retired from the London Health Sciences Centre (LHSC) or Western University (with an operational focus on pre-retirees aged 50 years and older).\n* The primary applicant (not their partner, if applicable) must be within two years before or after their retirement date.\n* Spouse or cohabitating partner of an enrolled primary participant. Cohabitating partners may include a common-law partner, adult child, close friend, or roommate who lives with the primary participant and shares common health goals. Enrollment of partners is optional but strongly encouraged.\n* Capable of providing informed consent.\n* Has access to a mobile device capable of receiving Short Message Service (SMS) communications and viewing PDF documents.\n* Physically able to safely engage in light-to-moderate intensity physical activity.\n\nExclusion Criteria:\n\n* Medical conditions that preclude safe participation in physical activity (for instance, unstable angina, uncontrolled arrhythmia, severe heart failure) without physician clearance.\n* Active or unstable psychiatric illness, defined as hospitalization for psychiatric care within the preceding 6 months or modifications to antipsychotic or mood-stabilizing pharmacotherapy within the preceding 3 months. Participants with stable, medically managed psychiatric conditions remain eligible.\n* Severe cognitive impairment that compromises the ability to provide informed consent or independently use study-related technology.\n* Inability to read and understand English sufficiently to provide informed consent and complete study procedures.",{"count":142,"type":23},120,[61],"Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging. To address this, we developed the BASIC-S framework, targeting Blood pressure, Activity, Sleep, Interaction (socially), Consumption (nutrition), and Support using partner support and motivational interviewing. This individual-focused approach bypasses the logistical and financial barriers of complex clinical interventions by using sustained behavioral science to support gradual lifestyle changes. This study is a single-center, mixed-methods, cluster-randomized pilot trial evaluating the feasibility of the BASIC-S protocol in an occupational setting. A maximum of 60 households (120 participants) will be randomized 1:1 to either the BASIC-S intervention (motivational coaching, secure video check-ins, automated text messages, and a digital workbook) or standard care. Outcomes will assess feasibility, acceptability, and the validity of new tracking metrics to inform a future full-scale trial.",[146,147,148,27,149,150],"Hypertension (HTN)","Vascular Diseases","Stroke","Cardiovascular Risk Factor","Cognitive Decline",[152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168],"Lifestyle Intervention","Motivational Interviewing","Primary Prevention","Behavioral Medicine","Brain Health","Cognition","Mental Health","Social Activity","Social Isolation","Physical Activity","Blood Pressure","Activity","Sleep","Interaction","Consumption","Support","Partnering",{"date":72,"type":39},{"date":171,"type":23},"2026-10-01",{"date":173,"type":23},"2027-10-01",{"name":175,"class":80},"Andrew Appleton",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":17,"sex":18,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":59,"phases":187,"briefSummary":188,"conditions":189,"keywords":192,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":47},"100604212","technology-based-intervention-usability-and-pilot-testing-100604212","NCT07146581","Technology-Based Intervention Pilot Testing","Primary Care Screening and Intervention for Caregiving Assessment and Support for Patients With Dementia: Technology-Based Intervention Usability and Pilot Testing","SIRENS","Caregiver Inclusion Criteria\n\n* 21 years old or older\n* Provides care for a patient of Weill Cornell Medicine\u002FNewYork-Presbyterian who meets the following criteria: (pilot only)\n\n  * Patient is at least 65 years old\n  * Patient has diagnosed dementia\n  * Patient requires assistance with at least 1 ADL\n* Self-identifies as primary informal caregiver for an older adult\n* Provides direct care (may include logistics, oversight, observation, as well as hands-on care, but must include at least some in-person assistance)\n* Can read and speak English at a 6th grade level or above\n* Not blind or deaf\n* No active plan to disengage from providing care to the older adult within the next year\n* Ability to travel to the COA or CABR for study activities and\u002For attend study session(s) virtually through Zoom on their personal device\n\nCaregiver Exclusion Criteria\n\n* Non-fluent English speaker\n* Hired caregiver\n* Provides care for a patient in hospice care\n* Too ill or weak to complete the interviews (per the interviewer)","21 Years",{"count":186,"type":23},40,[61],"This research project has three main goals:\n\n(1) To create a new screening tool that helps primary care doctors spot signs of neglect in older adults with dementia. (2) To design a support program that can be delivered both in person and through a mobile app on Android phones. (3) To run a clinical trial with three groups of participants to find out how effective the screening tool is on its own, and how effective it is when combined with the support program-compared to standard care.\n\nThis current phase of the project focuses on parts of goals 1 and 2, as described below.",[27,190,191],"Elder Abuse","Elder Neglect",[193,194],"Older Adults","Technology",{"date":36,"type":39},{"date":197,"type":23},"2026-09-15",{"date":199,"type":23},"2026-12-31",{"name":201,"class":80},"Weill Medical College of Cornell University",{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":17,"sex":18,"minAge":208,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":59,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":227},"100566080","effect-of-cognitive-empathy-training-on-dementia-caregivers-100566080","NCT06650527","Effect of Cognitive Empathy Training on Dementia Caregivers","Inclusion Criteria:\n\n* Caregivers must live with their care recipient\n* Caregivers must have a Zarit Burden Scale score of 19 or higher\n* Caregivers must have no plans to move their care recipient to an institutional setting within the next year\n* Caregivers must be able to read and write English\n* Care recipient not in hospice\n* Access to a mobile phone that can take and email photographs\n\nExclusion Criteria:\n\n* Subjects with a history of seizures or other neurological disorders, alcoholism, or any other substance abuse\n* Subjects with a history of psychiatric illness (excluding depression and anxiety disorders) will also be excluded\n* Subjects with a history of head trauma based on Survey\n* Subjects with MRI contra-indications","50 Years",{"count":210,"type":23},118,[61],"The goal of this project is to investigate the effect of cognitive empathy training on mental health, inflammation, and immune function in caregivers of people living with dementia (PLWD), and to examine the underlying psychological and neurobiological mechanisms.\n\nThe primary aim is to establish the effectiveness of cognitive empathy training in improving caregiver mental health and immune function, and in decreasing caregiver inflammation\n\nThe secondary aim is to investigate the psychological and neurobiological mechanism by which cognitive empathy training improves caregiver well-being",[214,27],"Caregivers of People Living With Dementia",[216,217,218],"Cognitive empathy","People Living With Dementia","Caregivers","2026-08-16",{"date":104,"type":39},{"date":222,"type":39},"2025-02-13",{"date":224,"type":23},"2028-11-01",{"name":226,"class":80},"Emory University",3,{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":59,"phases":236,"briefSummary":237,"conditions":238,"keywords":242,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":47},"100652450","a-mobile-informatics-solution-to-assist-caregivers-in-care-coordination-and-monitoring-social-engagement-100652450","NCT07773493","A Mobile Informatics Solution to Assist Caregivers in Care Coordination and Monitoring Social Engagement","Inclusion Criteria:\n\n* Persons with memory concerns must be English speaking.\n* Persons with memory concerns must self-report a healthcare provider visit due to memory concerns or memory related diagnosis by a physician or other qualified health care provider consistent with having mild-to-moderate memory impairment.\n* Persons with memory concerns must be over the age of 65.\n* Persons with memory concerns must be able to formally consent or assent to participate in the study.\n* Persons with memory concerns must have internet access.\n* Care partners of persons with memory concerns must speak English.\n* Care partners must be 18 years of age and over.\n* Care partners must self-identify as the primary caregiver for the person with memory concerns.\n* Care partners must indicate a willingness to use the Social Reminder System as well as to being randomized to a control group.\n* Care partners must have a mobile phone with internet access in order to install and use the care partner app.\n\nExclusion Criteria:\n\n* Those who do not meet the criteria above will be excluded.\n* Persons with memory concerns with severe or no dementia are not eligible.\n* Individuals who score below 6 and above 24 on the TICS-40 will not be eligible.",{"count":235,"type":23},200,[61],"This study will evaluate the Social Reminder System, a mobile informatics system designed to support persons with memory concerns and their care partners. The system is intended to aid social integration for persons with memory concerns and improve care coordination and reduce caregiver burden among caregivers.\n\nResearchers will enroll 100 persons with memory concerns and their care partners. Half of the dyads will be randomly assigned to receive the Social Reminder System technology for a 6-month period, and the other half will be randomly assigned to the usual care control group. Participants will complete baseline, 3-month, and 6-month surveys. A subset of participants who receive the technology will also be asked to complete a semi-structured interview after the 6-month survey.",[239,240,27,160,241],"Memory Disorders","Mild Cognitive Impairment","Caregiver Burden",[243,244,245,246,247,248,249,250,251],"Social Reminder System","SRS","Persons with memory concerns","Social engagement","Mobile health","Care coordination","Alzheimer's disease and related dementias","Mild-to-moderate memory impairment","Caregiver stress","2026-08-14",{"date":72,"type":39},{"date":255,"type":23},"2026-11-01",{"date":257,"type":23},"2028-06",{"name":259,"class":80},"University of Minnesota",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":59,"phases":270,"briefSummary":272,"conditions":273,"keywords":277,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":47},"100392965","phase-1-pet-imaging-of-cyclooxygenases-in-neurodegenerative-brain-disease-100392965","NCT04396873","PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","* INCLUSION CRITERIA:\n\nPatients: In order to be eligible to participate in this study, patients must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Be able (or have their Legally Authorized Representative (LAR) be able) to understand the study and be willing to sign a written informed consent document.\n3. Have been diagnosed by a neurologist or psychiatrist with MCI, ALS, PD, or an adult onset neurodegenerative dementia, such as AD (including amyloid negative subjects), FTD, corticobasal syndrome, or Huntington s disease.\n4. Be in good general health as evidenced by medical history and physical examination.\n5. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n6. Agree to adhere to the lifestyle considerations.\n\nHealthy volunteers: In order to be eligible to participate in this study, healthy volunteer subjects must meet all of the following criteria:\n\n1. Aged 18 or older.\n2. Female participants of childbearing potential must be using a medically acceptable means of contraception\n3. Able provide informed consent.\n4. Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment.\n5. Be enrolled in 01-M-0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17-M-0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies\n6. Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists.\n7. Agree to adhere to the lifestyle considerations.\n\nEXCLUSION CRITERIA:\n\nBoth patients and healthy volunteers who meet any of the following criteria will be excluded from participation in this study:\n\n1. Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two-times the upper limit or even lower values in the investigator s judgment. Creatinine level \\>1.3 mg\u002FdL\n2. Subjects should not have taken Non-Steroidal Anti-Inflammatory Drugs (NSAID) for two weeks prior to the PET scan. Aspirin, corticosteroids (with the exception of skin products), or immunosuppressants (e.g., methotrexate) must not have been taken in the prior month.\n3. Contraindications to ketoprofen, such as hypersensitivity to ketoprofen or history of upper or lower gastrointestinal bleeding.\n4. Have other major neurological or medical diseases that may cause cognitive dysfunction, such as structural brain diseases, metabolic diseases, paraneoplastic syndromes, infectious diseases, or other significant neurological abnormalities.\n5. Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy).\n6. Are unable to travel to the NIH.\n7. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits.\n8. Have an inability to lie flat and\u002For lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the patient and\u002For caregiver during the screening visit.\n9. Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life.\n10. Participants should not be under treatment with Aduhelm, nor should they have been treated in the past.\n11. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye).\n12. Pregnancy\n13. HIV infection\n14. Be NIMH staff or an NIH employee who is a subordinate\u002Frelative\u002Fco-worker of the investigators.","99 Years",{"count":269,"type":23},184,[271],"PHASE1","Background:\n\nAbout 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.\n\nObjective:\n\nTo learn whether COX-1 and\u002For COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers.\n\nEligibility:\n\nAdults age 18 years and older in good general health who have an adult-onset neurodegenerative dementia, such as AD, FTD, corticobasal syndrome, Huntington s disease, or MCI, ALS and healthy adult volunteers enrolled in protocols 01-M-0254 or 17-M-0181.\n\nDesign:\n\nParticipants will be screened with medical history, physical exam with vital signs, and lab tests. They will have a neuropsychological testing. Their heart function will be measured.\n\nParticipants will have a magnetic resonance imaging (MRI) scan. The MRI scanner is a metal tube surrounded by a strong magnetic field. Participants will lie on a table that slides in and out of the tube. The machine makes noise. Participants will get earplugs.\n\nParticipants will have 2 PET scans. They will be injected with the study drugs through an intravenous catheter placed in an arm vein. The PET scanner is shaped like a doughnut. Participants will lie on a bed that slides in and out of the scanner. A plastic mask will be molded to their head to keep them from moving. A thin plastic tube will be put into an artery at the wrist or elbow crease area. This will be used to draw blood during the scan.\n\nParticipants will have 2-5 study visits. Participation lasts 1 week to 4 months, depending on scheduling.",[274,27,275,276,240],"Parkinson's Disease","Alzheimer's Disease","ALS",[278,279,280,27,281,276,282],"PET Imaging","PD","Inflammation","Cyclooxygenase-2","MCI",{"date":284,"type":39},"2026-08-17",{"date":286,"type":39},"2021-08-17",{"date":288,"type":23},"2030-10-03",{"name":290,"class":46},"National Institute of Mental Health (NIMH)",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":301,"conditions":302,"keywords":308,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":47},"100651643","establishing-normal-cognitive-test-scores-for-adults-using-a-voice-enabled-digital-testing-platform-across-the-lifespan-100651643","NCT07763392","Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digital Testing Platform Across the Lifespan","Establishment of Age-, Sex-, and Education-Stratified Normative Data for a Fully Digital Voice-Recognized Neurocognitive Testing Platform in Adults Aged 18-100 Years","Inclusion Criteria:\n\n* Adults aged 18 to 100 years at the time of enrollment.\n* Able to read, speak, and understand English sufficiently to complete all study procedures.\n* Able and willing to provide informed consent.\n* Adequate hearing, speech, and vision (with corrective devices if needed) to complete computerized voice-recognition cognitive testing.\n* Able to independently complete the digital cognitive assessment using a computer, tablet, or smartphone with internet access (or at a supervised study site if applicable).\n\nExclusion Criteria:\n\n* Known Cognitive Impairment Self-reported or previously diagnosed cognitive impairment, memory disorder, mild cognitive impairment, or dementia.\n* Neurological Disease or Brain Injury History of a neurological condition or brain injury that, in the opinion of the investigator, may adversely affect cognitive performance.\n* Psychiatric Illness Current or untreated psychiatric illness that may significantly influence cognitive testing performance.\n* Substance Use or Cognitive-Impacting Medications Current use of substances or medications known to significantly impair cognition or recent substance use that could affect test validity.\n* Sensory or Communication Limitations Inadequate English proficiency or speech, hearing, or visual impairments that would prevent valid completion of the digital cognitive assessment.\n* Functional or Medical Conditions Affecting Cognition Medical conditions or functional impairments that, in the opinion of the investigator, may interfere with accurate assessment of normal cognitive performance.\n* Investigator Discretion Any other condition or circumstance that, in the judgment of the Principal Investigator, would compromise participant safety, study compliance, or the validity of the normative dataset.","100 Years",{"count":300,"type":23},1000,"Trial weblink: https:\u002F\u002Fwww.memoryexam.com\u002Fjob\u002Fnorms\u002F\n\nParticipants enrolled in this study will complete a single-session, non-invasive, computerized cognitive assessment administered through a secure, web-based digital platform. The purpose of the study is to establish normative cognitive performance data from healthy adults aged 18-100 years and develop age-, sex-, and education-adjusted reference values for the digital assessment platform. This is an observational study and does not involve any therapeutic intervention, investigational treatment, or alteration of routine medical care.\n\nFollowing electronic informed consent, participants will complete a standardized screening questionnaire to determine eligibility. The questionnaire collects demographic information, education, English language proficiency, medical and neurological history, psychiatric history, medication use, substance use, sleep history, and self-reported cognitive concerns. Standardized mood screening instruments (PHQ-9 and GAD-7) are also administered. Individuals meeting predefined exclusion criteria that could significantly influence cognitive performance will not be included in the normative dataset.\n\nEligible participants will then complete a digital cognitive assessment battery using standardized visual and auditory instructions. The platform utilizes automated voice-recognition technology to capture spoken responses and standardized algorithms to score performance, eliminating the need for examiner scoring and ensuring consistent administration across participants. Total study participation, including consent, screening, and testing, is approximately 30 to 45 minutes.\n\nThe cognitive battery evaluates multiple cognitive domains commonly assessed during neuropsychological examinations. Language abilities are assessed through phonemic and semantic verbal fluency tasks, measuring the ability to rapidly generate words within specified categories. Confrontation naming is evaluated using digitally presented images that participants identify verbally. Learning and memory are assessed through immediate and delayed verbal recall tasks, including recognition memory measures. Attention and working memory are evaluated using forward and backward digit span tasks. Executive functioning and attention are further assessed using a brief computerized problem-solving task. Equivalent alternate versions of selected tasks may be administered to minimize practice effects while measuring the same cognitive domains. All assessments are brief, non-invasive, and completed using spoken responses.\n\nThe platform automatically records participant responses, response timing, and scoring metrics. Voice recordings are collected solely to support automated scoring and quality assurance. All electronic data are transmitted using encrypted connections and stored within HIPAA-aligned cloud infrastructure. Personally identifiable information is stored separately from cognitive performance data using unique study identification numbers, and only authorized study personnel have access to identifiable information. De-identified data will be used to generate normative reference values.\n\nA subset of approximately 100 participants may be invited to complete a second assessment 2-4 weeks after the initial visit to evaluate test-retest reliability. Participation in this follow-up assessment is voluntary.\n\nParticipants will not receive diagnostic results or individualized interpretations of their performance because the study is intended solely to establish normative reference data. If responses on the PHQ-9 suggest potential acute self-harm risk, the platform will provide crisis resources and notify the study team in accordance with the study safety procedures.\n\nThe primary outcome of the study is the development of age-, sex-, and education-adjusted normative reference values for the digital cognitive assessment platform, supporting standardized interpretation of future assessments in clinical and research settings.",[157,303,304,27,305,306,307],"Cognition Disorders","Cognition - Other","Alzheimer Disease","Memory","Neurocognition",[306,157,27,275,309],"Normal","2026-08-13",{"date":284,"type":39},{"date":313,"type":39},"2026-03-23",{"date":315,"type":23},"2027-03-23",{"name":317,"class":80},"The Neurology Center of Southern California",{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":59,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":47},"100649943","medication-collaboration-feasibility-study-100649943","NCT07742189","Medication Collaboration Feasibility Study","Feasibility Study of a Brief Intervention to Support Medication Collaboration Among Older Adults and Family Care Partners","Inclusion Criteria for older adults with dementia:\n\n1. Age 60 or older\n2. Diagnosis of dementia, Alzhimer's Disease or Mild Cognitive Impairment\n3. Quick Dementia Rating Scale Score 2-12 (inclusive of mild cognitive impairment and mild dementia)\n4. Taking 3 or more medications\n5. Involved with managing their medications\n6. Proficient speaking English\n7. Capacity to provide consent\n\nInclusion criteria for caregivers include::\n\n1. Primary family caregiver for the past 3 months\n2. Age 18 or older\n3. Proficient speaking English\n\nExclusion Criteria:\n\n* adults unable to consent",{"count":326,"type":23},30,[61],"This study examines the feasibility and acceptability of a brief medication collaboration intervention among older adults (age 60+) with early-stage dementia or mild cognitive impairment who take multiple medications and their family caregivers. The main aims are to: 1) determine the feasibility and acceptability of the intervention for older adults with early-stage dementia and their family caregivers, and 2) explore the effects of intervention on medication collaboration, medication adherence, and beliefs about dementia and autonomy.\n\nIn this study, participants will: 1) complete a 15-30-minute baseline interview (by Zoom or phone), 2) participate together in a 45-60-minute virtual intervention led by an interventionist that includes:\n\nAssessment of medication responsibilities and beliefs. Education about dementia and medication management. Cognitive restructuring to address beliefs about independence and caregiver assistance.\n\nCollaborative planning for medication responsibilities and routines; and lastly 3) complete a 15-20-minute one-month follow-up interview (by Zoom or phone) to assess the intervention's acceptability and changes in medication management outcomes.",[330,27,331],"Dementia Family Caregiver","Medication Adherence",{"date":252,"type":39},{"date":334,"type":39},"2026-08-03",{"date":336,"type":23},"2026-12",{"name":338,"class":80},"Northwestern University",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":347,"targetDuration":349,"studyType":24,"phases":4,"briefSummary":350,"conditions":351,"keywords":354,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":47},"100550540","multimodal-assesment-of-alzheimer-patients-100550540","NCT06448403","Multimodal Assesment of Alzheimer Patients","Multimodal Assessment of Cognitive Impairment in Alzheimer Patients","MultiAD","Inclusion Criteria:\n\n* MCI and AD according to relevant ICD-criterias.\n* Control cohort is age and gender matched with other cohorts.\n\nExclusion Criteria:\n\n* Uneligibility for any of the planned neuroimagery devices (MRI, EEG)\n* AD diagnosis before the age of 65 (Early-onset AD).\n* Brain tumor\n* Traumtic head injury\n* Earlier neurosurgery\n* Other neyrodegenerative diseases (i.e Parkinson and ALS)\n* Diseases related to inflammation and auto-immunity (i.e MS)",{"count":348,"type":23},60,"5 Years","The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD).\n\nThe main questions the study aims to answer are:\n\n1. What findings can be used to earlier detect patients that will develop Alzheimers?\n2. Which differences are seen between healthy and cognitively impaired patients?\n3. Which differences are seen between patients with Alzheimers disease?\n\nParticipants will undergo:\n\n* Cognitive tests\n* Magnetic resonance imaging (MRI)\n* Electroencephalography (EEG)\n* Blood sample collection\n* Fecal sample collection\n* A randomized group will undergo polysomnography analysis.",[240,352,353,27],"Alzheimer Disease, Late Onset","Cognitive Impairment",[355,356,357,358,359,27,360],"Alzheimer Disease (AD)","Mild cognitive impairment (MCI)","Brain Diseases","Nervous System Disorders","Neurodegenerative Diseases","Cognitive impairment","2026-08-12",{"date":310,"type":39},{"date":364,"type":39},"2024-07-01",{"date":366,"type":23},"2030-12-29",{"name":368,"class":80},"Norwegian University of Science and Technology",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":59,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":47},"100484769","dementia-care-partner-hospital-assessment-tool-100484769","NCT05592366","Dementia Care Partner Hospital Assessment Tool","Adapting and Testing the Care Partner Hospital Assessment Tool for Use in Dementia Care","Inclusion Criteria:\n\n* Provide unpaid care to a hospitalized adult relative or partner to help them take care of themselves because of ADRD\n* 18 years or older\n\nExclusion Criteria:\n\n* Non-English speaking",{"count":377,"type":23},128,[61],"The purpose of this study is to see whether an adapted questionnaire called the Care Partner Hospital Assessment Tool (CHAT) for care partners of hospitalized patients living with Alzheimer's disease and related dementias (ADRD) (CHAT-AD) can help people with dementia receive better care after they go home from the hospital. Participants will be a care partner ('family member or friend') who provides unpaid care to a hospitalized adult relative or partner to help them take care of themselves because of dementia. Participants can expect to be in this study for 14 days.",[305,27],{"date":252,"type":39},{"date":383,"type":39},"2024-04-02",{"date":385,"type":23},"2027-05",{"name":387,"class":80},"University of Wisconsin, Madison",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":59,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":404,"leadSponsor":406,"locationsCount":47},"100579096","acute-hospital-care-at-home-for-people-living-with-dementia-100579096","NCT06819852","Acute Hospital Care at Home for People Living With Dementia","Skipping the Hospital: Acute Hospital Care at Home for People Living With Dementia","Inclusion Criteria:\n\n* Diagnosis of moderate or severe dementia (as ascertained by the Quick Dementia Rating System; QDRS)\n* Resides in a private or assisted living residence with or nearby (\\\u003C15min travel time) to a family caregiver\n* Resides within the Mass General Brigham (MGB) home hospital catchment area\n* Has had at least 1 hospitalization in the last 12 months.\n\nExclusion Criteria:\n\n* Hospitalized in the last 30 days\n* No functioning utilities, such as no working heat (October-April), no running water, or no electricity.\n* Resides in skilled nursing facility\n* Resides in group home\n* Domestic violence screen positive\n* In police custody\n* Family caregiver unable to initiate or maintain communication with care team\n* End-stage renal disease on hemodialysis\n* On methadone requiring daily pickup of medication\n* Active substance use disorder, without functioning treatment plan\n* Psychiatric diagnosis that would prohibit successful home hospital care\n* Acute delirium without explanation or without the ability to manage at home\n* Patients with cancer requiring consistent hospital-based treatments\n* Cannot ambulate to bedside commode with assistance present in the home (if different from baseline), unless home-based aides are available",{"count":235,"type":23},[61],"The investigators will perform a parallel-group multicenter randomized controlled trial of a 1-year pre-enrolled acute hospital care at home intervention vs usual care for people living with dementia. Patients will be randomized only after eligibility determination and after the family caregiver agrees to enroll; people living with dementia will assent when able. Patients will be allocated in a concealed fashion to the control and intervention groups in randomly selected block sizes of 4 or 6 in 4 strata reflecting their functional status (activities of daily living: 0, 1, 2-3, 4-6). Although family and clinicians cannot be blinded, the investigators will blind the data collectors and assessors.",[399,400,27],"Emergency Department Visit","Home Care Services","2026-08-10",{"date":361,"type":39},{"date":284,"type":23},{"date":405,"type":23},"2029-04-01",{"name":407,"class":80},"Brigham and Women's Hospital",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":59,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":47},"100628402","penn-state-emergency-medicine-cares-care-partner-evaluation-and-sourcing-in-the-emergency-department-100628402","NCT07461168","Penn State Emergency Medicine CarES: Care-partner Evaluation and Sourcing in the Emergency Department","Penn State Emergency Medicine CarES: Care-partner Evaluation and Sourcing in the ED","CarES","Inclusion Criteria:\n\n* Person completed the CarES Observational Study.\n* Person is a care partner and:\n* Lives with the person living with dementia or\n* Checks on them at least once per week in person or by phone\n* Person is willing and able to participate in study assessments\n\nExclusion Criteria:\n\n* Person is no longer a care partner for a person living with dementia\n* Person declines participation",{"count":417,"type":23},20,[61],"Care partners of people living with dementia often experience ongoing stress and unmet support needs. This study evaluates the feasibility of a low-intensity, supportive education and resource intervention for care partners who previously participated in an observational study.\n\nParticipants complete a baseline phone interview and a short stress journaling activity, followed by a six-week series of automated educational and supportive messages delivered by text message or email. Participants may also take part in an optional peer support focus group. The study examines caregiver stress, resilience, engagement with resources, and participant feedback to inform future caregiver support interventions.",[27,421,241,422],"Caregiver Stress","Caregiver Burden of People With Dementia","2026-08-06",{"date":401,"type":39},{"date":426,"type":23},"2026-08-31",{"date":428,"type":23},"2026-12-30",{"name":430,"class":80},"Milton S. Hershey Medical Center",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":267,"enrollmentInfo":439,"targetDuration":4,"studyType":59,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":454},"100651299","lived-experience-narratives-in-dementia-100651299","NCT07757178","Lived Experience Narratives in Dementia","Improving the Quality of Life for People Living With Dementia and Carers: The Design and Development of a Dementia Specific Online Narrative-Based Intervention With a Feasibility Study","LEND","General Inclusion Criteria (apply across WP1-WP3)\n\n* Adults aged 18+.\n* Able to give informed consent and participate meaningfully in the required tasks.\n* Adequate communication ability in the required study language\n\nGeneral Exclusion Criteria (apply across WP1-3)\n\n* Living in a hospital or healthcare institution at the time of the study.\n* Refusal or inability to provide informed consent, or lack of capacity to consent.\n* Inability to comprehend participant information or communicate meaningfully",{"count":348,"type":23},[61],"The Lived Experience Narratives in Dementia (LEND) research programme involves five work packages (WP). WP1 explores how people living with dementia use narratives and how narratives can impact them. Findings will support the development of LEND theory. WP 2-3 focus on developing the digital Online LEND Intervention, assessing its usability and acceptability, and conducting a feasibility study within NHS memory assessment and community services. Activities across the first three WPs include interviews, focus groups, user-testing sessions, engagement evaluation interviews, and a two-arm randomised feasibility trial using a range of outcome measures. Findings from this stage will inform refinement of the intervention and determine the feasibility of progressing to a future randomised controlled trial (RCT) of the Online LEND Intervention. WP4 is the Online LEND Intervention two-arm RCT. WP5 involves dissemination. The protocol for WP4 and 5 have not yet been developed and rely on results from WP1-3.",[27,443,305,241,444],"Neuro-Degenerative Disease","Caregiver Burnout","2026-08-05",{"date":447,"type":39},"2026-08-11",{"date":449,"type":39},"2025-11-17",{"date":451,"type":23},"2029-07",{"name":453,"class":80},"University of Nottingham",2,{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":182,"eligibilityCriteria":461,"healthyVolunteers":17,"sex":18,"minAge":184,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":59,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":470,"leadSponsor":472,"locationsCount":47},"100651208","primary-care-screening-and-intervention-for-patients-with-dementia-and-caregivers-100651208","NCT07758738","Primary Care Screening and Intervention for Patients With Dementia and Caregivers","Primary Care Screening and Intervention for Caregiving Assessment and Support for Patients With Dementia: Randomized Controlled Trial","Primary care provider Inclusion Criteria • Active PCP who may be a physician or nurse practitioner seeing adult primary care patients with dementia at: Weill Cornell Medicine\n\nPrimary care provider Exclusion Criteria\n\n• Not a PCP of older adults with dementia who may be at risk of being neglected.\n\nOlder Adult Inclusion Criteria:\n\n* Aged ≥ 60 years\n* Community-dwelling\n* Patient of WCM\u002FNYP\n* Has diagnosis of dementia (based on medical records prior to enrollment)\n* Requires assistance with at least 1 ADL\n* Able to travel to a WCM\u002FNYP clinic for study activities\n* Has informal (either unpaid or CDPAP) caregiver who provides ≥8 hours weekly\n* Not already known to be experiencing neglect from caregiver\n\nOlder Adult Exclusion Criteria:\n\n* In hospice\n* Decision has already been made to re-locate to an institution (including long-term care skilled nursing facilities)\n\nCaregiver Inclusion Criteria:\n\n* Age ≥ 21 years\n* Living with or near the older adult\n* Self-identifies as a caregiver for the older adult\n* Provides ≥ 8 hours per week of direct care (may include logistics, oversight, observation, as well as hands-on care, but must include at least some in-person assistance)\n* Able to travel to a WCM\u002FNYP clinic for study activities or participate in study activities virtually through Zoom on their personal device\n* Not a professional caregiver, does not receive direct payment in return for care (unless through CDPAP)\n* Can read and speak English at a 6th grade level\n* No active plan to disengage from providing care to older adult within the next year\n\nCaregiver Exclusion Criteria:\n\n* Unable to read and speak English at a 6th grade level\n* Hired\u002Fpaid professional caregiver\n* Is blind or deaf\n* Active plan to disengage from providing care to older adult within the next year",{"count":463,"type":23},774,[61],"The goal of this clinical trial is to evaluate the impact of screening for elder neglect in older adults with dementia in primary care settings and the impact of an intervention for caregivers of older adults with dementia.\n\nThe hypothesis of the study are:\n\n* Neglect screening in primary care will have a positive impact on outcomes including a decrease in presence of neglect at 6 months and other patient and caregiver outcomes\n* Neglect screening paired with a caregiving intervention will have a greater impact on these outcomes than screening alone\n\nResearchers will compare three groups of participants to find out how effective the screening tool is on its own, and how effective it is when combined with the support program, compared to standard care.\n\nParticipants will be asked to:\n\n* attend primary care clinic visits\n* complete questionnaires\n* participate in the intervention\n* participate in a semi-structured interview",[27,190,467],"Elder Mistreatment",{"date":447,"type":39},{"date":255,"type":23},{"date":471,"type":23},"2027-07-31",{"name":201,"class":80},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":59,"phases":480,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":47},"100619280","the-weact-program-for-family-caregivers-of-people-living-with-dementia-100619280","NCT07342569","The WeACT Program for Family Caregivers of People Living With Dementia","Inclusion criteria\n\nFamily caregivers of people living with dementia will be eligible to participate if they meet all of the following criteria:\n\n1. Are community-dwelling adults aged 18 years or older who have primary caregiving responsibilities for a relative diagnosed with dementia;\n2. Present mild to moderately severe depressive symptoms, as measured by the Patient Health Questionnaire-9 (PHQ-9), with scores between 5 and 19; and\n3. Have access to a web-enabled device, such as a smartphone, tablet, laptop, or desktop computer, with internet access.\n\nExclusion criteria\n\nFamily caregivers of people living with dementia will be excluded if they meet any of the following criteria:\n\n1. Have cognitive, physical, or sensory impairments, or are unable to complete study procedures in English, that may impede study participation;\n2. Present severe depressive symptoms, defined as PHQ-9 scores of 20 or higher;\n3. Report having thoughts of harming themselves or attempting suicide within the past six months;\n4. Have previously participated in a research study involving an ACT program;\n5. Are currently participating in another caregiver intervention study; or\n6. Have experienced more than three hospitalizations of either the family caregiver or the relative with dementia within the past year.",{"count":186,"type":23},[61],"The goal of this clinical trial is to learn whether WeACT, a self-paced, web-based program, is feasible and helpful for adult family caregivers of a relative living with dementia. WeACT is based on acceptance and commitment therapy (ACT), which teaches skills to handle difficult thoughts and feelings and take steps toward what matters most.\n\nThe main questions this study aims to answer are:\n\n* Can caregivers complete WeACT as planned?\n* Do caregivers show improvements in mental health and coping after using WeACT?\n* What are caregivers' experiences with the program, and what suggestions do they have to improve it?\n\nParticipants will:\n\n* Complete six self-paced weekly online modules and use the daily practice section during the program.\n* Complete online questionnaires before starting and after completing the program.\n* Take part in one online interview about their experience.",[483,218,27],"Depression",[485,486,487,488,489,490,491,492,493,494],"acceptance and commitment therapy","Internet-Based Intervention","caregivers","dementia","depressive symptoms","feasibility","usability","web-based intervention","mixed methods","Pilot Study",{"date":496,"type":39},"2026-08-04",{"date":498,"type":23},"2026-08",{"date":500,"type":23},"2027-02",{"name":502,"class":80},"University of South Florida",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":59,"phases":513,"briefSummary":514,"conditions":515,"keywords":518,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":47},"100649261","animal-assisted-therapy-combined-with-standard-rehabilitation-for-motor-recovery-in-dementia-patients-in-a-medical-and-rehabilitation-care-unit-100649261","NCT07730983","Animal-Assisted Therapy Combined With Standard Rehabilitation for Motor Recovery in Dementia Patients in a Medical and Rehabilitation Care Unit","Impact of a Combined Rehabilitation and Animal-Assisted Therapy Approach on the Recovery of Motor Abilities in Patients With Dementia Hospitalized in a Medical and Rehabilitation Care Unit","RéMédi - A","Inclusion Criteria:\n\n* Hospitalized in the geriatric medical and rehabilitation ward (SMR) of Institut Médical de Sologne (IMDS)\n* Diagnosed dementia or confirmed cognitive decline, shown by a score between 15 and 24 on the Mini-Mental State Examination (MMSE - a short standardized test of memory and thinking)\n* Has active motor rehabilitation goals (identified need to improve movement abilities during hospitalization)\n* Participant and\u002For their legal guardian, trusted person (personne de confiance), curator, or family member has provided written consent to participate in the study\n* Affiliated to a French social security scheme\n\nExclusion Criteria:\n\n* Known allergy to the animals used in the animal-assisted therapy sessions (dog, rabbits)\n* Fear of animals\n* History of aggressive behavior toward animals\n* Concomitant psychiatric disorders\n* Needs only a stimulation and\u002For skills maintenance approach (no active motor rehabilitation goals)\n* Currently enrolled in another interventional research study\n\n(Note: A participant who was previously enrolled in another interventional study may join RÉMÉDI-A once their participation in the prior study has ended, without a washout period, provided all eligibility criteria are met.)",{"count":512,"type":23},32,[61],"The goal of this randomized study is to find out if animal-assisted therapy (AAT) - a structured program where trained animals take part in care sessions guided by health professionals - can help improve movement abilities in older adults with dementia or memory-related conditions who are staying in a medical rehabilitation unit.\n\nThe main questions this study aims to answer are:\n\n* Can adding animal-assisted therapy to standard rehabilitation improve participants' movement and motor abilities better than standard rehabilitation alone?\n* Can this combined approach help participants stay more independent in daily activities?\n* Can this combined approach improve participants' quality of life?\n* Can this combined approach reduce the risk of falls?\n\nResearchers will compare two groups:\n\n* Group 1 (experimental): Standard rehabilitation + animal-assisted therapy sessions with a trained dog and\u002For rabbits\n* Group 2 (control): Standard rehabilitation alone\n\nBoth groups attend 2 one-hour rehabilitation sessions per week for 4 weeks.\n\nParticipants will:\n\n* Complete movement and daily-life ability tests at the start and end of the study\n* Attend 8 rehabilitation sessions (over 4 weeks)\n* Participants in the animal therapy group will interact with a trained dog and\u002For rabbits during sessions, guided by a certified nurse-animal therapist, a psychomotor therapist, and a nursing assistant\n* Be assessed at the end of the 4-week program (Week 6) to measure any changes in motor abilities, independence, quality of life, and fall risk",[27,516,517],"Cognitive Dysfunction ( MMSE \u003C 24 )","Motor Skills Disorders",[27,519,520,521,522,523,150,524],"Animal-Assisted Therapy","Motor Rehabilitation","Psychomotor Function","Geriatric Rehabilitation","Non-Pharmacological Intervention","Medical and Rehabilitation Care","2026-07-23",{"date":527,"type":39},"2026-07-28",{"date":529,"type":23},"2026-09",{"date":531,"type":23},"2027-12",{"name":533,"class":80},"LNA SANTE",{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":59,"phases":543,"briefSummary":544,"conditions":545,"keywords":549,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":560,"locationsCount":561},"100649134","protocolized-receptive-music-intervention-to-reduce-care-refusal-in-nursing-home-residents-with-major-neurocognitive-disorders-100649134","NCT07730957","Protocolized Receptive Music Intervention to Reduce Care Refusal in Nursing Home Residents With Major Neurocognitive Disorders","Impact of Protocolizing Receptive Music Intervention on Care Refusal During Hygiene Care in Nursing Home Residents With Major Neurocognitive Disorders","OPPOZIC'","RESIDENT ELIGIBILITY\n\nInclusion Criteria:\n\n* Living in a LNA Santé EHPAD (nursing home) as a permanent resident for at least 3 months\n* Diagnosed Alzheimer's disease or a related disorder, or confirmed cognitive decline shown by a Mini-Mental State Examination (MMSE - a short memory and thinking test) score of 24 or less within the past 12 months (including cases where the MMSE cannot be administered due to severe cognitive impairment)\n* Showing care refusal behavior, defined as an Agitation\u002FAggression item score on the NPI-ES scale (frequency × severity) greater than or equal to 4 at the time of inclusion\n* Resident and\u002For their legal representative or trusted person has given written consent to participate\n* Affiliated to a French social security scheme\n\nExclusion Criteria:\n\n* Uncompensated hearing loss with sensory isolation (unable to benefit from music therapy)\n* Documented end-of-life status in the medical record\n\nCAREGIVER ELIGIBILITY\n\nInclusion Criteria (Caregivers):\n\n* Adult (18 years of age or older)\n* Working in the care unit of an enrolled resident and performing hygiene\u002Fnursing care (bathing)\n* Able to read and write French\n* Affiliated to a French social security scheme\n* Has given written consent to participate\n\nExclusion Criteria (Caregivers):\n\n* Employment contract shorter than the resident's 3-month study follow-up period (i.e., unable to complete all 3 caregiver assessments)\n* Unable to provide informed consent to participate\n* Under legal protection as defined by Article 1121-8 of the French Public Health Code (under legal guardianship or deprived of liberty)\n* Not affiliated to a French social security scheme",{"count":348,"type":23},[61],"The goal of this randomized study is to find out whether using a structured, protocolized music program (MUSIC CARE©) during daily hygiene care can reduce care refusal in older adults with dementia (memory and thinking conditions) who live in nursing homes (EHPADs).\n\nWhat is \"care refusal\"? Care refusal (also called resistance to care) happens when a person with dementia refuses or becomes distressed during everyday care activities such as bathing, dressing, or taking medications. It is a very common situation in nursing homes that can be stressful for both residents and care staff.\n\nThe main questions this study aims to answer are:\n\n* Can a structured, daily music program reduce care refusal during bathing and hygiene care compared to current practice?\n* Does using music for 20 minutes during the care session work as well as - or differently from - using it both before and during care (40 minutes total)?\n* Does the music program also reduce distressing behavioral symptoms in residents?\n* Does it reduce the need for sedative or psychiatric medications?\n* Does it reduce professional burnout in caregivers who perform hygiene care?\n\nResearchers will compare three groups:\n\n* Group 1 (Control): Current practice - care staff may use MUSIC CARE© at their own discretion, as they already do\n* Group 2 (Music During Care): Structured use of MUSIC CARE© for 20 minutes during every hygiene care session, daily for 4 weeks\n* Group 3 (Music Before + During Care): Structured use of MUSIC CARE© for 20 minutes before and 20 minutes during every hygiene care session (40 minutes total), daily for 4 weeks\n\nNursing homes (not individual residents) are randomly assigned to a group.\n\nResidents and their caregivers will:\n\n* Have their level of care refusal recorded daily for 4 weeks\n* Have neuropsychiatric symptoms and medication use assessed at the start, Week 4, and Week 8\n* Caregivers will also complete a confidential and anonymous professional burnout questionnaire at 3 time points",[27,546,547,548],"Cognitive Dysfunction","Psychomotor Agitation","Burnout, Professional",[27,550,551,552,523,553,554,555],"Music Therapy","Care Refusal","Receptive Music Intervention","Behavioral and Psychological Symptoms of Dementia","Nursing Home","Professional Burnout",{"date":527,"type":39},{"date":558,"type":39},"2025-10-30",{"date":77,"type":23},{"name":533,"class":80},12,{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":59,"phases":572,"briefSummary":575,"conditions":576,"keywords":579,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":599},"100565847","phase-2-a-study-of-a-potential-disease-modifying-treatment-in-individuals-at-risk-for-or-with-a-type-of-early-onset-ad-caused-by-a-genetic-mutation-100565847","NCT06647498","A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation","A Phase II\u002FIII Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease","DIAN-TU-002","Inclusion Criteria:\n\n1. Provide written informed consent, signed, and dated by the participant and study partner, or by the participant's legally authorized representative if applicable, according to local regulations for the ICF and, if applicable, country specific ICFs.\n2. Participant is at least 18 years old.\n3. People of childbearing potential\n\n   1. Must have a negative serum pregnancy test at screening (V1)\n   2. Must agree not to try to become pregnant from the time of signed ICF until twenty (20) weeks after the last dose of any study drug.\n   3. Must agree not to breastfeed from the time of signed ICF until twenty (20) weeks after the last dose of any study drug.\n   4. If partner is not sterilized, must agree to use highly effective contraceptive measures, methods that can achieve a failure rate of less than 1% per year when used consistently and correctly from screening (V1) until twenty (20) weeks after last dose of any study drug.\n\n   i. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal ii. progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable iii. intra-uterine device (IUD) iv. intrauterine hormone-releasing systems (IUS) v. bilateral tubal occlusion vi. vasectomized partner (only when this is the only partner) vii. true sexual abstinence when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, post-ovulation methods\\], declaration of abstinence for the duration of exposure to IMP, and withdrawal are not acceptable methods of contraception)\n4. Mutation Status:\n\n   1. Participant is a carrier of a mutation in an APP, PSEN1, or PSEN2 gene that is associated with DIAD or does not know their mutation status and there is a mutation in their family pedigree that puts them at a direct risk of inheriting the known mutation;\n   2. Participant is -25 to -11 years from predicted age of cognitive symptom onset based on their mutation type or family pedigree Note: If the at-risk parent is deemed a non-carrier through confirmed genetic testing at any time during the study, the participant will be withdrawn.\n5. Cognitive status of participant is normal (CDR-SB 0).\n6. Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning. Participants must be fluent in languages for which cognitive and clinical measures have been translated and validated for use in the DIAN-TU. Fluency is generally defined as daily or frequent functional use of a language generally from birth or a young age. In cultures where multiple languages are spoken or for participants who are multilingual, determination as to whether a participant's level of fluency in languages for which clinical and cognitive measures are available meets qualification for the study should be made by the site PI.\n7. Adequate visual and auditory abilities to perform all aspects of the cognitive and clinical assessments.\n8. Receiving stable doses of medication(s) for the treatment of non-excluded medical condition(s) for at least 30 days prior to baseline visit (V2) with the exceptions of medications taken for episodic conditions (e.g., migraine abortive therapy, antibiotics, and other medications for upper respiratory and gastrointestinal ailments).\n9. Has a study partner who in the PI's judgment can provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at the study visits that require study partner input for scale completion, and who signs the necessary ICF, if applicable.\n10. Agrees not to donate blood or blood products for transfusion from the time of Screening (V1) for a study drug arm, for the duration of the study, and for 5 half lives after the final dose of study drug.\n11. In the opinion of the PI, the participant will be compliant and have a high probability of completing the study.\n12. Willing to complete all study-related testing, evaluations, and procedures.\n\nExclusion Criteria:\n\n1. Significant neurologic disease (other than AD) or psychiatric disease that may currently or during the study affect cognition or the participant's ability to complete the study. This would include disorders such as: recent or severe head trauma causing cognitive change, seizure disorder, neurodegenerative disease other than DIAD, hydrocephalus, cerebral\u002Fspinal hematoma, inflammatory disease, CNS infection (e.g., encephalitis or meningitis), neoplasm, toxic exposure, metabolic disorder (including hypoxic or hypoglycemic episodes) or endocrine disorder; psychiatric disorders such as schizophrenia, schizoaffective disorder, bipolar disorder or major depression, or any other psychiatric condition\u002Fdisorder which could significantly interfere with the participant's cooperative participation (e.g., prominent anxiety, agitation or behavioral problems).\n\n   Disorders that are controlled medically or remote history of these disorders (e.g., history of febrile seizures in childhood) that are not likely to interfere with cognitive function and compliance with study procedures are not exclusionary.\n2. At high risk for suicide, e.g., significant suicidal ideation or attempt within last 12 months, current major depression (as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition \\[DSM-V\\]), or increased suicide risk based on screening Columbia Suicide Severity Rating Scale (C-SSRS). Current stable mild depression or current use of antidepressant medications are not exclusionary.\n3. History of clinically evident stroke or history of clinically important carotid or vertebrobasilar stenosis, plaque, or other prominent risk factor for stroke or cerebral hemorrhage (including atrial fibrillation and anticoagulation, documented transient ischemic attack \\[TIA\\] in the last 12 months) that may be interfering with cognition or is likely to impact with the participant's ability to complete the study.\n4. Alcohol or substance use sufficient to meet DSM-V criteria currently or within the past year.\n5. History of or Baseline (V2) visit brain MRI scan indicative of any other significant abnormality, definite microhemorrhages, evidence of a cerebral contusion, encephalomalacia, or aneurysms. Minor or clinically insignificant imaging findings are not exclusionary.\n6. Presence of certain implanted medical devices, such as some pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or body which would preclude MRI scan.\n7. Cardiovascular complications such as uncontrolled hypertension, history of myocardial infarcts, heart failure, atrial fibrillation, long QT interval on ECG likely to interfere with participation in or analysis of the trial in the opinion of the investigator\n8. Hepatic or renal abnormalities that in the opinion of the investigator would interfere with participation in or analysis of the trial.\n9. History of Human Immunodeficiency Virus (HIV) infection, history of Hepatitis B infection within the past year, history of Hepatitis C infection which has not been adequately treated, history of spirochete infection (e.g., syphilis, Lyme) of the CNS or history of other infection with high risk for interfering with participation or interpretation of the study in the opinion of the investigator.\n10. History of clinically significant multiple or severe drug allergies, significant atopy, or severe post-treatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and\u002For exfoliative dermatitis) or sensitivity to study-drug specific PET imaging agents with a high risk for interfering with participation or interpretation of the study in the opinion of the investigator.\n11. Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within 90 days prior to Baseline (V2) visit (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years.\n12. Current clinically significant abnormalities of thyroid function, or clinically significant deficiency in vitamin B12. Vitamin B12 less than the lower limits of normal with normal methylmalonic acid (MMA)\u002Fhomocysteine is not deemed clinically significant, therefore not exclusionary.\n13. Unstable or poorly controlled diabetes which the investigator believes may interfere with participation in or analysis of the study protocol. Participants may be rescreened after 3 months to allow optimization of diabetic control\n14. Morbid obesity with significant comorbidities or that would preclude MRI imaging.\n15. Current use of anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, or apixaban). Daily use of low dose (\\\u003C 325 mg) aspirin is not exclusionary.\n16. Have been exposed to a monoclonal antibody targeting Aβ peptide within the past 6 months or 5 half-lives from screening, whichever is longer.\n17. Received any other investigational pharmacological treatment within 3 months of Screening or 5 half-lives, whichever is longer.\n\n    Note: Use of approved treatments for AD and other medications may be permitted in this study.\n18. Lack of sufficient venous access.\n19. Clinically relevant abnormalities in hematology, coagulation, or clinical chemistry.\n20. History of cancer that the investigator believes has high risk of recurrence and impacting study participation or analysis.\n21. Any other medical condition that could be expected to progress, recur, or change to such an extent that it could bias the assessment of the clinical or mental status of the participant to a significant degree or put the participant at special risk.\n22. Currently, or within the last month prior to screening, participated in a clinical study, including a nonpharmacological study, without prior approval.\n23. Participants with the \"Dutch\" APP E693Q mutation.\n24. Unable to complete baseline visit (V2) procedures with appropriate cognitive and clinical scores for eligibility\n25. A centrally read MRI demonstrating presence of ARIA-E, \\> 4 cerebral microhemorrhages, any superficial siderosis, any macrohemorrhage, or severe white matter disease at screening.\n26. Exposure to lecanemab, donanemab, or other investigational amyloid lowering agents within the past 6 months or five half-lives from screening, whichever is longer.\n27. Investigator site personnel directly affiliated with this trial and\u002For their immediate families, defined as a spouse, parent, child, or sibling, whether biological or legally adopted\n28. Lilly employees or employees of a third-party organization (TPO) involved in this study that requires exclusion of their employees or have study partners who are Lilly employees or are employees of TPOs involved in this study that require exclusion of their employees",{"count":571,"type":23},280,[573,574],"PHASE2","PHASE3","The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug.\n\nStage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD).\n\nStage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.",[577,27,578],"Alzheimers Disease","Alzheimers Disease, Familial",[580,275,27,581,582,583,584,585,586,587,588,589,590],"Alzheimer's","Mutation","Genetic Mutation","Dominantly Inherited Alzheimer's Disease","Dominantly Inherited Alzheimer Network","Autosomal Dominant Alzheimer's Disease","Early Onset Alzheimer's Disease","DIAN","DIAN-TU","DIAN TU","DIAD",{"date":592,"type":39},"2026-07-27",{"date":594,"type":39},"2024-11-22",{"date":596,"type":23},"2034-08",{"name":598,"class":80},"Washington University School of Medicine",37,{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":567,"acronym":588,"eligibilityCriteria":605,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":606,"targetDuration":4,"studyType":59,"phases":607,"briefSummary":608,"conditions":609,"keywords":610,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":613,"leadSponsor":615,"locationsCount":599},"100481680","phase-2-a-study-of-potential-disease-modifying-treatments-in-individuals-at-risk-for-or-with-a-type-of-early-onset-ad-caused-by-a-genetic-mutation-100481680","NCT05552157","A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation","Inclusion Criteria:\n\n1. Provide written informed consent, signed, and dated by the participant and study partner, or by the participant's legally authorized representative if applicable, according to local regulations for the ICF and, if applicable, country specific ICFs.\n2. Participant is at least 18 years old.\n3. People of childbearing potential\n\n   1. Must have a negative serum pregnancy test at screening (V1)\n   2. Must agree not to try to become pregnant from the time of signed ICF until twenty (20) weeks after the last dose of any study drug.\n   3. Must agree not to breastfeed from the time of signed ICF until twenty (20) weeks after the last dose of any study drug.\n   4. If partner is not sterilized, must agree to use highly effective contraceptive measures, methods that can achieve a failure rate of less than 1% per year when used consistently and correctly from screening (V1) until twenty (20) weeks after last dose of any study drug.\n\n   i. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal ii. progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable iii. intra-uterine device (IUD) iv. intrauterine hormone-releasing systems (IUS) v. bilateral tubal occlusion vi. vasectomized partner (only when this is the only partner) vii. true sexual abstinence when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, post-ovulation methods\\], declaration of abstinence for the duration of exposure to IMP, and withdrawal are not acceptable methods of contraception)\n4. Mutation Status:\n\n   1. Participant is a carrier of a mutation in an APP, PSEN1, or PSEN2 gene that is associated with DIAD or does not know their mutation status and there is a mutation in their family pedigree that puts them at a direct risk of inheriting the known mutation;\n   2. Participant is -25 to -11 years from predicted age of cognitive symptom onset based on their mutation type or family pedigree Note: If the at-risk parent is deemed a non-carrier through confirmed genetic testing at any time during the study, the participant will be withdrawn.\n5. Cognitive status of participant is normal (CDR-SB 0).\n6. Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning. Participants must be fluent in languages for which cognitive and clinical measures have been translated and validated for use in the DIAN-TU. Fluency is generally defined as daily or frequent functional use of a language generally from birth or a young age. In cultures where multiple languages are spoken or for participants who are multilingual, determination as to whether a participant's level of fluency in languages for which clinical and cognitive measures are available meets qualification for the study should be made by the site PI.\n7. Adequate visual and auditory abilities to perform all aspects of the cognitive and clinical assessments.\n8. Receiving stable doses of medication(s) for the treatment of non-excluded medical condition(s) for at least 30 days prior to baseline visit (V2) with the exceptions of medications taken for episodic conditions (e.g., migraine abortive therapy, antibiotics, and other medications for upper respiratory and gastrointestinal ailments).\n9. Has a study partner who in the PI's judgment can provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at the study visits that require study partner input for scale completion, and who signs the necessary ICF, if applicable.\n10. Agrees not to donate blood or blood products for transfusion from the time of Screening (V1) for a study drug arm, for the duration of the study, and for 5 half lives after the final dose of study drug.\n11. In the opinion of the PI, the participant will be compliant and have a high probability of completing the study.\n12. Willing to complete all study-related testing, evaluations, and procedures.\n\nExclusion Criteria:\n\n1. Significant neurologic disease (other than AD) or psychiatric disease that may currently or during the study affect cognition or the participant's ability to complete the study. This would include disorders such as: recent or severe head trauma causing cognitive change, seizure disorder, neurodegenerative disease other than DIAD, hydrocephalus, cerebral\u002Fspinal hematoma, inflammatory disease, CNS infection (e.g., encephalitis or meningitis), neoplasm, toxic exposure, metabolic disorder (including hypoxic or hypoglycemic episodes) or endocrine disorder; psychiatric disorders such as schizophrenia, schizoaffective disorder, bipolar disorder or major depression, or any other psychiatric condition\u002Fdisorder which could significantly interfere with the participant's cooperative participation (e.g., prominent anxiety, agitation or behavioral problems).\n\n   Disorders that are controlled medically or remote history of these disorders (e.g., history of febrile seizures in childhood) that are not likely to interfere with cognitive function and compliance with study procedures are not exclusionary.\n2. At high risk for suicide, e.g., significant suicidal ideation or attempt within last 12 months, current major depression (as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition \\[DSM-V\\]), or increased suicide risk based on screening Columbia Suicide Severity Rating Scale (C-SSRS). Current stable mild depression or current use of antidepressant medications are not exclusionary.\n3. History of clinically evident stroke or history of clinically important carotid or vertebrobasilar stenosis, plaque, or other prominent risk factor for stroke or cerebral hemorrhage (including atrial fibrillation and anticoagulation, documented transient ischemic attack \\[TIA\\] in the last 12 months) that may be interfering with cognition or is likely to impact with the participant's ability to complete the study.\n4. Alcohol or substance use sufficient to meet DSM-V criteria currently or within the past year.\n5. History of or Baseline (V2) visit brain MRI scan indicative of any other significant abnormality, definite microhemorrhages, evidence of a cerebral contusion, encephalomalacia, or aneurysms. Minor or clinically insignificant imaging findings are not exclusionary.\n6. Presence of certain implanted medical devices, such as some pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or body which would preclude MRI scan.\n7. Cardiovascular complications such as uncontrolled hypertension, history of myocardial infarcts, heart failure, atrial fibrillation, long QT interval on ECG likely to interfere with participation in or analysis of the trial in the opinion of the investigator\n8. Hepatic or renal abnormalities that in the opinion of the investigator would interfere with participation in or analysis of the trial.\n9. History of Human Immunodeficiency Virus (HIV) infection, history of Hepatitis B infection within the past year, history of Hepatitis C infection which has not been adequately treated, history of spirochete infection (e.g., syphilis, Lyme) of the CNS or history of other infection with high risk for interfering with participation or interpretation of the study in the opinion of the investigator.\n10. History of clinically significant multiple or severe drug allergies, significant atopy, or severe post-treatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and\u002For exfoliative dermatitis) or sensitivity to study-drug specific PET imaging agents with a high risk for interfering with participation or interpretation of the study in the opinion of the investigator.\n11. Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within 90 days prior to Baseline (V2) visit (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years.\n12. Current clinically significant abnormalities of thyroid function, or clinically significant deficiency in vitamin B12. Vitamin B12 less than the lower limits of normal with normal methylmalonic acid (MMA)\u002Fhomocysteine is not deemed clinically significant, therefore not exclusionary.\n13. Unstable or poorly controlled diabetes which the investigator believes may interfere with participation in or analysis of the study protocol. Participants may be rescreened after 3 months to allow optimization of diabetic control\n14. Morbid obesity with significant comorbidities or that would preclude MRI imaging.\n15. Current use of anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, or apixaban). Daily use of low dose (\\\u003C 325 mg) aspirin is not exclusionary.\n16. Have been exposed to a monoclonal antibody targeting Aβ peptide within the past 6 months or 5 half-lives from screening, whichever is longer.\n17. Received any other investigational pharmacological treatment within 3 months of Screening or 5 half-lives, whichever is longer.\n\n    Note: Use of approved treatments for AD and other medications may be permitted in this study.\n18. Lack of sufficient venous access.\n19. Clinically relevant abnormalities in hematology, coagulation, or clinical chemistry.\n20. History of cancer that the investigator believes has high risk of recurrence and impacting study participation or analysis.\n21. Any other medical condition that could be expected to progress, recur, or change to such an extent that it could bias the assessment of the clinical or mental status of the participant to a significant degree or put the participant at special risk.\n22. Currently, or within the last month prior to screening, participated in a clinical study, including a nonpharmacological study, without prior approval.\n23. Participants with the \"Dutch\" APP E693Q mutation.\n24. Unable to complete baseline visit (V2) procedures with appropriate cognitive and clinical scores for eligibility",{"count":571,"type":23},[573,574],"The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction\u002Fprevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.",[577,27,578],[580,275,27,581,582,583,584,585,586,587,588,589,590],{"date":592,"type":39},{"date":594,"type":39},{"date":614,"type":23},"2034-08-30",{"name":598,"class":80},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":18,"minAge":88,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":59,"phases":625,"briefSummary":626,"conditions":627,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":637},"100505256","phase-2-testing-the-pain-clinical-practice-guideline-100505256","NCT05858996","Testing the Pain Clinical Practice Guideline","Testing the Pain Clinical Practice Guideline Using the Evidence Integration Triangle","Inclusion Criteria:\n\n* Living in a participating community\n* 60 years of age or older\n* Evidence of dementia based on a score of 0-12 on the Brief Interview of Mental Status (BIMS); a score of \\>2 on the AD8 Dementia Screening Interview; a score of 0.5 to 2.0 on the Clinical Dementia Rating Scale (CDR); and lastly to differentiate between dementia and mild cognitive impairment a score of 9 or greater on the Functional Activities Questionnaire (FAQ).\n* have evidence of pain at the time of recruitment based on the Minimum Data set assessment item: How much of the time over the past 5 days have you experienced pain or hurting with eligibility based on the following responses or evidence: occasionally, frequently or almost constantly, or staff report of pain at the same frequency; or if the resident is receiving nonpharmacological or pharmacological treatment for pain.\n\nExclusion Criteria:\n\n* admitted to the nursing home for short-stay rehabilitation or other subacute needs (e.g., intravenous antibiotics);\n* receiving Hospice care.",{"count":624,"type":23},300,[573],"There are evidence based processes for assessment and management of pain using pharmacologic and nonpharmacological approaches. These were reviewed and included within the Pain Management Clinical Practice Guideline (Pain Management CPG) recently developed by AMDA: The Society for Post-Acute and Long-Term Care Medicine. There are, however, many challenges to translating the use of Clinical Practice Guidelines into clinical settings. To overcome these challenges we developed and previously tested a theoretically based approach and merged this approach with the Pain Management CPG, which is referred to as the PAIN-CLINICAL PRACTICE GUIDELINE-USING THE EVIDENCE INTEGRATION TRIANGLE (PAIN-CPG-EIT). The PAIN-CPG-EIT involves a research nurse facilitator working with an identified community champion(s) and stakeholder team for 12 months to provide the following four components: Component I: Establishing and meeting monthly with a Stakeholder Team; Component II: Education of the staff; Component III: Mentoring and motivating the staff to address pain; Component IV: Ongoing evaluation of resident pain outcomes. Twelve communities will be included with 25 residents living with dementia and pain recruited from each community. Six communities will be randomized to treatment (PAIN-CPG-EIT) and six randomized to education only (EO) which involves providing the same education to staff as is done in Component II of PAIN-CPG-EIT. The primary aim of this study is to test the effectiveness of use of the PAIN-CPG-EIT to improve the assessment, diagnosis and management of pain and decrease pain intensity among nursing home residents living with dementia between baseline, 4 and 12 months and evaluate treatment fidelity. A secondary aim of the study is to consider differences in measurement, treatment and response to treatment between male and female and Black versus White residents living with dementia. Findings from this study will help build on the currently limited information about pain presentation and management among older adults living with dementia in nursing homes and improve health equity of aging populations experiencing pain.",[628,27],"Pain","2026-07-22",{"date":525,"type":39},{"date":632,"type":39},"2023-12-01",{"date":634,"type":23},"2028-12-31",{"name":636,"class":80},"University of Maryland, Baltimore",11,{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":18,"minAge":646,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":649,"conditions":650,"keywords":652,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":47},"100601743","delirium-and-cognitive-impairment-development-in-hospitalized-older-adults-under-isolation-conditions-100601743","NCT07114458","Delirium and Cognitive Impairment Development in Hospitalized Older Adults Under Isolation Conditions","Delirium Incidence and Cognitive Trajectories in Isolated Older Patients in the Inpatient Setting","DELiso","Inclusion Criteria: - hospitalized patients\n\n* under isolation precautions for at least 24h\n* 70 years and above\n\nExclusion Criteria: - no informed consent\n\n* intensive care treatment\n* life expectancy 14 days or less","70 Years",{"count":648,"type":23},404,"The goal of this observational study is to examine if older patients who need to be under isolation precautions due to multidrug resistant bacteria or other reasons have an increased risk of suffering from delirium or cognitive decline compared to older patients without isolation precautions.\n\nTo compare this, every person under isolation precautions is compared to other persons of the same age, gender, comorbidities, frailty status and hospital department. Delirium is assessed twice daily with a screening tool named 3D-CAM and cognitive performance is tested by the MOCA-Test six weeks after discharge from hospital and compared to baseline values which are assessed directly after study enrollment.\n\nThe study duration for each patient participating is from the time of enrollment during hospitalization until 6 weeks after hospital discharge.",[651,27,353],"Delirium",[651,653,654,655],"neurocognitive disorder","older adult","isolation precautions","2026-07-21",{"date":525,"type":39},{"date":659,"type":39},"2025-08-05",{"date":661,"type":23},"2027-11",{"name":663,"class":80},"Universitätsklinikum Hamburg-Eppendorf",{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":669,"acronym":4,"eligibilityCriteria":670,"healthyVolunteers":12,"sex":18,"minAge":118,"maxAge":119,"enrollmentInfo":671,"targetDuration":4,"studyType":59,"phases":673,"briefSummary":674,"conditions":675,"keywords":676,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":679,"lastUpdatePostDateStruct":680,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":47},"100648279","neuromodulation-for-behavioral-changes-in-neurological-disorders-100648279","NCT07718906","Neuromodulation for Behavioral Changes in Neurological Disorders","A Prospective Early Feasibility Study of Focused Ultrasound Neuromodulation for Emotional Dysregulation Due to Dementia.","* Age 45-80 years at time of enrollment.\n* Diagnosis of probable mild-stage neurodegenerative dementia, including Alzheimer's disease (AD), frontotemporal dementia (FTD, including behavioral variant and language variant), or dementia with Lewy bodies (LBD), based on established consensus clinical criteria.\n* Presence of clinically meaningful (in treatment for or recommended for the symptoms) neuropsychiatric or behavioral symptoms including but not limited to anxiety, agitation, depression, irritability, apathy, or disinhibition\n* Able to undergo MRI scanning\n* Adequate auditory and visual abilities to complete study procedures as determined by the investigator.\n* Availability of a study partner (legally authorized representative, caregiver, or family member) who has regular contact with the participant and can provide collateral information and assist with assessments.\n* Ability to provide informed consent, or assent with legally authorized representative (LAR) consent in accordance with WVU IRB policy and applicable West Virginia law. .Currently under the care of a licensed physician, psychiatrist, or neurologist, and agrees to allow communication between investigators\u002Fstudy staff and healthcare providers for purposes of eligibility confirmation and safety monitoring.\n\nEXCLUSION CRITERIA\n\n* Moderate to severe dementia (i.e., beyond mild stage).\n* Clinically significant MRI abnormality that may jeopardize participant safety, study conduct, or confound diagnostic assessments.\n* History of clinically significant neurological disorder other than the qualifying dementia diagnosis that could confound evaluation or increase risk.\n* Major psychiatric disorder that would interfere with participation or safety, including psychosis, active suicidal ideation, or severe mood\u002Fanxiety disorder requiring immediate intervention.\n* Elevated suicide risk with History of medically verified suicide attempt within the past year.\n* Use of medications that significantly lower the seizure threshold or interfere with neuromodulation safety, as determined by the study physician.\n* Use of investigational drugs or participation in another interventional clinical trial within 30 days prior to screening.\n* Any condition that, in the opinion of the investigator, would interfere with study participation, safety, or interpretation of results.",{"count":672,"type":23},15,[61],"The purpose of this study is to see if a focused ultrasound neuromodulation can be safely and effectively used to treat symptoms of emotional dysregulation such as agitation, irritability and anxiety",[27],[677,678],"Neuromodulation","Focused Ultrasound","2026-07-16",{"date":629,"type":39},{"date":682,"type":23},"2026-07-25",{"date":684,"type":23},"2028-12-30",{"name":686,"class":80},"West Virginia University"]